TAIPEI, Taiwan, SHANGHAI, China and SAN FRANCISCO, California — May 28, 2026
HanchorBio, Inc. announced that the company will officially list on the Taiwan Innovation Board on May 29, 2026, with an underwriting price of NT$120 per share, as the clinical-stage biotechnology company advances global development and partnering activities for its lead immunotherapy candidate HCB101. The listing represents a significant financing milestone for HanchorBio while ongoing clinical data from HCB101 continue to support expanding global licensing and co-development discussions.
HCB101 Clinical Data Strengthens Global Partnering Potential
HanchorBio’s lead oncology program, HCB101, is a CD47-targeting anti-cancer biologic engineered to block tumor immune-evasion signals and restore macrophage-mediated tumor phagocytosis. The therapy is currently being evaluated in multinational Phase 1b/2a clinical studies across multiple cancer indications including gastric cancer, head and neck cancer, colorectal cancer, and triple-negative breast cancer.
According to the company, interim data from a mid-dose cohort evaluating HCB101 in combination with standard second-line gastric cancer therapy demonstrated an encouraging objective response rate (ORR) of 80%, alongside favorable safety and tumor reduction findings. Preliminary data from additional gastric cancer and first-line triple-negative breast cancer cohorts also showed promising disease control and anti-tumor activity.
HanchorBio stated that early proof-of-concept clinical data continue to play an important role in ongoing discussions with global pharmaceutical companies regarding regional and worldwide rights to HCB101 outside already licensed territories. The company believes additional supportive Phase 2a clinical results may further strengthen future licensing, co-development, and strategic transaction opportunities.
Advertisement
Taiwan Innovation Board Listing Expands Capital Market Access
The Taiwan Innovation Board listing is expected to enhance HanchorBio’s long-term financing flexibility and increase visibility among biotechnology investors as the company continues advancing its immunotherapy pipeline. Founder, Chairman, and Chief Executive Officer Scott Liu, Ph.D. stated that platform-based biotechnology models capable of generating multiple therapeutic assets may help diversify development risk while supporting sustainable long-term growth.
HanchorBio’s proprietary FBDB™ platform is designed to create multifunctional biologic therapies by integrating multiple immune-modulating mechanisms into a single molecule. The platform supports development across oncology and autoimmune diseases while enabling structural optimization for safety, exposure, and manufacturability.
The company’s broader pipeline includes HCB301, a trifunctional fusion protein currently in Phase 1 clinical trials in the United States, mainland China, and Taiwan, along with additional programs including HCB303 and autoimmune-focused candidate HCB206.
Licensing Activity and Pipeline Expansion Continue
HanchorBio continues pursuing a multi-indication development and commercialization strategy for HCB101 aimed at supporting flexible business development opportunities globally. The company previously entered into a licensing agreement with Henlius valued at up to US$202 million, granting rights for development and commercialization of HCB101 in mainland China and selected territories.
Management confirmed that ongoing partnering discussions with several pharmaceutical companies continue as demand grows for differentiated immunotherapy platforms targeting difficult-to-treat cancers. The company believes its combination of clinical-stage assets, platform technology, and newly expanded access to public capital markets positions HanchorBio for continued growth within the global biotechnology sector.
Source: HanchorBio press release
